logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11680087 B1

PDFFull Text
Date of Patent:
Jun. 20, 2023

Filed:

Dec. 18, 2020

Compositions and methods thereof

Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Annaliesa Sybil Anderson, Upper Saddle River, NJ (US);

Rasappa Gounder Arumugham, Lansdale, PA (US);

John Erwin Farley, Chapel Hill, NC (US);

Leah Diane Fletcher, Geneseo, NY (US);

Shannon Lea Harris, Nanuet, NY (US);

Kathrin Ute Jansen, New York, NY (US);

Thomas Richard Jones, New City, NY (US);

Lakshmi Khandke, Nanuet, NY (US);

Bounthon Loun, North Reading, MA (US);

John Lance Perez, Doylestown, PA (US);

Gary Warren Zlotnick, San Antonio, TX (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:

Matthew J. Pugmire

Primary Examiner:

S Devi

Int. Cl.
CPC ...
A61K 39/05 (2006.01); C07K 14/22 (2006.01); A61K 39/00 (2006.01); A61K 39/13 (2006.01); A61K 39/295 (2006.01); A61K 39/095 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/22 (2013.01); A61K 39/0016 (2013.01); A61K 39/095 (2013.01); A61K 39/12 (2013.01); A61K 39/13 (2013.01); A61K 39/295 (2013.01); A61K 39/39 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/70 (2013.01); C12N 2710/20034 (2013.01); C12N 2770/32634 (2013.01); Y02A 50/30 (2018.01);
Abstract

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

Find Patent Forward Citations

Loading…